Labcorp launched two new circulating tumor DNA assays — Plasma Detect ID (personalized whole‑exome guided panels) and Plasma Detect Genome (whole‑genome MRD) — to broaden its MRD portfolio across breast, lung and colon cancers. The company touts sub‑0.005% ctDNA sensitivity and supporting clinical studies. Saga Diagnostics extended its Pathlight MRD assay to colorectal cancer following positive CITCCA data, while Watchmaker Genomics released four RPA enzymes aimed at point‑of‑care isothermal diagnostics. These commercial moves reflect diagnostics companies pushing MRD and decentralized testing into clinical workflows and payer discussions.